Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Review, H2 2015’, provides an overview of the Anaplastic Large Cell Lymphoma (ALCL)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Large Cell Lymphoma (ALCL) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Anaplastic Large Cell Lymphoma (ALCL)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Anaplastic Large Cell Lymphoma (ALCL) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Anaplastic Large Cell Lymphoma (ALCL) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Anaplastic Large Cell Lymphoma (ALCL) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Anaplastic Large Cell Lymphoma (ALCL)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Anaplastic Large Cell Lymphoma (ALCL) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Anaplastic Large Cell Lymphoma (ALCL) Overview
Therapeutics Development
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Overview
Pipeline Products for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Development by Companies
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics under Investigation by Universities/Institutes
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Anaplastic Large Cell Lymphoma (ALCL) - Products under Development by Companies
Anaplastic Large Cell Lymphoma (ALCL) - Products under Investigation by Universities/Institutes
Anaplastic Large Cell Lymphoma (ALCL) - Companies Involved in Therapeutics Development
Akron Molecules AG
AstraZeneca Plc
Bayer AG
Celon Pharma Sp. z o.o.
Pfizer Inc.
Sareum Holdings Plc
Seattle Genetics, Inc.
Teva Pharmaceutical Industries Limited
Anaplastic Large Cell Lymphoma (ALCL) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AdIL-24 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKR-302 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AKR-303 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AZD-3463 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
brentuximab vedotin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-28122 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CEP-37440 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
copanlisib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
crizotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug to Inhibit ALK for Anaplastic Large Cell Lymphoma - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KRA-0008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SH-7129 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Aurora and ALK Kinase for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Aurora Kinase and FLT3 Kinase for Oncology - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Anaplastic Large Cell Lymphoma (ALCL) - Recent Pipeline Updates
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products
Anaplastic Large Cell Lymphoma (ALCL) - Product Development Milestones
Featured News & Press Releases
Jun 17, 2015: Seattle Genetics Announces Multiple ADCETRIS (Brentuximab Vedotin) Data Presentations at the International Conference on Malignant Lymphoma
Dec 07, 2014: Seattle Genetics and Takeda Announce Four-Year Survival Data from ADCETRIS (Brentuximab Vedotin) Pivotal Trial in Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma at ASH Annual Meeting
Dec 06, 2014: Seattle Genetics and Takeda Report Phase 3 AETHERA Clinical Trial Data from ADCETRIS (Brentuximab Vedotin) in Post-Transplant Hodgkin Lymphoma Patients at Risk of Relapse at ASH Annual Meeting
Nov 07, 2014: Seattle Genetics to Present Clinical Data from Broad ADCETRIS (Brentuximab Vedotin) Development Program and Novel Antibody-Drug Conjugates at ASH 2014
Nov 06, 2014: Takeda Announces Abstracts for ADCETRIS (brentuximab vedotin) in Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma to be Presented at 56th American Society of Hematology Annual Meeting
Sep 24, 2014: Seattle Genetics Highlights Updated Progression-Free Survival and Overall Survival Data from ADCETRIS (Brentuximab Vedotin) Frontline PTCL Phase 1 Clinical Trial at the ESMO 2014 Congress
Apr 17, 2014: ADCETRIS 50mg for intravenous drip infusion, Treatment for Patients with CD30 Positive Relapsed or Refractory Hodgkin Lymphoma or Relapsed or Refractory Anaplastic Large Cell Lymphoma Now Available in Japan
Jan 17, 2014: Seattle Genetics Announces ADCETRIS Approval in Japan for the Treatment of Relapsed or Refractory Hodgkin Lymphoma and Anaplastic Large Cell Lymphoma
Jun 21, 2013: Seattle Genetics Highlights Adcetris Clinical Data At International Conference On Malignant Lymphoma
Jun 19, 2013: Takeda And Seattle Genetics Highlight Post-Hoc Analysis Examining Progression-free Survival With Adcetris At International Conference On Malignant Lymphoma
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Akron Molecules AG, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by AstraZeneca Plc, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Bayer AG, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Celon Pharma Sp. z o.o., H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Pfizer Inc., H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Sareum Holdings Plc, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Seattle Genetics, Inc., H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) Therapeutics - Recent Pipeline Updates, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Dormant Projects, H2 2015
Anaplastic Large Cell Lymphoma (ALCL) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL), H2 2015
Number of Products under Development for Anaplastic Large Cell Lymphoma (ALCL) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook